Connecticut-based Biohaven Pharmaceutical Holding Co. Ltd. has paid $105m for a US FDA priority review voucher that it intends to use in the second quarter of 2019 to speed the regulatory review of its oral migraine candidate rimegepant. Use of the voucher could cut the review period from 10 to six months.
Since the use of a voucher to expedite a new drug application requires 90 days’ notice, it would appear that Biohaven intends to file rimegepant in the latter part of June 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?